3rd How to Diagnose and Treat
CML/MPN
March 3-5, 2023 – Berlin, Germany
Chairs: Claire Harrison (London), Andreas Hochhaus (Jena), Ruben Mesa (Winston Salem)

Friday, March 3, 2023

08:30-08:40	**Welcome**	Conference Chairpersons

SESSION I – New approaches for MPNs
Chair: Claire Harrison (London)

08:40-08:47	Interactive case Difficult case in MPN	Claire Harrison (London)
08:47-08:50	*Discussion*	
08:50-09:10	Case-based lecture Targeting hepcidin pathway in polycythemia vera	Marina Kremyanskaya (New York)
09:10-09:15	*Discussion*	
09:15-09:35	Case-based lecture Moving beyond hydroxyurea in essential thrombocythemia	Ruben Mesa (Winston Salem)
09:35-09:40	*Discussion*	
09:40-10:00	Case-based lecture Combination approaches for myelofibrosis	Naveen Pemmaraju (Houston)
10:00-10:05	*Discussion*	
10:05-10:12	Interactive case Secondary or other erythrocytosis	Mary Frances McMullin (Belfast)
10:12-10:15	*Discussion*	
10:15-10:20	Brief oral communication Transfusion independence: potential surrogate for overall survival (OS) in JAK inhibitor (JAKi)--experienced patients with myelofibrosis (MF) from MOMENTUM	Ruben Mesa (Winston Salem)
10:20-10:23	*Discussion*	
10:23-10:28	Brief oral communication Burden of disease and incremental burden of transfusion dependence in myelofibrosis: a US-based claims analysis	Claire Harrison (London)
10:28-10:31	*Discussion*	
10:31-10:50	*Panel discussion*	

10:50-11:15 Coffee Break

SESSION II – CML first line therapy
Chair: Annamaria Brioli (Greifswald)

11:15-11:22	Interactive case Tumour lysis syndrome	Annamaria Brioli (Greifswald)
11:22-11:25	*Discussion*	
11:25-11:45	Case-based lecture Nilotinib + PEG-IFN alpha 2a - the PETALS trial	Franck Nicolini (Lyon)
11:45-11:50	*Discussion*	
11:50-12:10	Case-based lecture Interferon alpha in combination - the TIGER trial	Andreas Hochhaus (Jena)
12:10-12:15	*Discussion*	
12:15-12:35	Case-based lecture Dose optimization Dasatinib - the DasaHIT trial	Paul La Rosée (Villingen-Schwenningen)
12:35-12:40	*Discussion*	
12:40-12:47	Interactive case Autoimmune disease caused by IFN	Daniela Zackova (Brno)
12:47-12:50	*Discussion*	

12:50-13:20 Panel discussion

13:20-15:15 Lunch

14:00-15:00 **SATELLITE SYMPOSIUM**
Holistic treatment of MF: going beyond splenomegaly and symptoms
Chair: Haifa Kathrin Al-Ali (Leipzig)
Speakers: Francesca Palandri (Bologna), Heinz Gisslinger (Vienna), Haifa Kathrin Al-Ali (Leipzig)

This symposium is organized and sponsored by GSK

SESSION III – CML in advanced disease
Chair: Paul La Rosée (Villingen-Schwenningen)

15:15-15:22	Interactive case Advanced CML	Fausto Castagnetti (Bologna)
15:22-15:25	*Discussion*	
15:25-15:45	Case-based Lecture CML blast crisis - the European registry	Annamaria Brioli (Greifswald)
15:45-15:50	*Discussion*	
15:50-16:10	Case-based lecture Accelerated phase vs. high-risk disease - the new WHO classification	Jane Apperley (London)
16:10-16:15	*Discussion*	

16:15-16:35	Case-based lecture CML: cytogenetic and molecular evolution	Katerina Machova (Prague)
16:35-16:40	*Discussion*	
16:40-16:47	Interactive case BCR::ABL1 independent mutation	Philipp Ernst (Jena)
16:47-16:50	*Discussion*	
16:50-17:20	*Panel discussion*	

17:20-17:50 Coffee break

17:50-18:30 DEBATE 1 – Treatment goals in myelofibrosis
Chair: Ruben Mesa (Winston Salem)

Audience votes

17:50-18:05	Disease modification is the universal goal in myelofibrosis	Adam Mead (Oxford)
18:05-18:20	Individualized therapy best for myelofibrosis	John Mascarenhas (New York)
18:20-18:30	*Discussion*	

Audience votes again

18:30-19:10 ROUNDTABLE 1 – When & how to initiate treatment
Chair: Alessandro Vannucchi (Florence)

18:30-18:40	Chronic myelomonocytic leukaemia	Daniel Wiseman (Manchester)
18:40-18:50	Polycythemia vera and essential thrombocythemia	Alessandro Vannucchi (Florence)
18:50-19:00	Atypical CML	Carlo Gambacorti-Passerini (Milan)
19:00-19:10	*Discussion*	

19:10-20:20 ***Poster Walk and Welcome Get Together stand-up buffet***
Poster Walk leaders: Claire Harrison (London), Andreas Hochhaus (Jena),
Ruben Mesa (Winston Salem)

Saturday, March 4, 2023

07:50-08:50 Simultaneous Meet the Expert sessions

1. Mastocytosis	Deepti Radia (London)
2. Eosinophilic Disorders	Andreas Reiter (Mannheim)
3. Managing Pregnancy in MPNs and CMLs	Elisabetta Abruzzese (Rome)

09:00-10:00 **SATELLITE SYMPOSIUM**
Unanswered Questions in MF: Disease modifying potential of existing and novel therapies
Chairs & Speakers: Adam Mead (Oxford), Vikas Gupta (Toronto)

This symposium is organized and sponsored by AbbVie

10:00-10:30 Coffee Break

SESSION IV – New drugs in CML
Chair: Philipp Le Coutre (Berlin)

10:30-10:37	Interactive case Allogeneic stem cell transplantation or next drug?	Philipp Le Coutre (Berlin)
10:37-10:40	*Discussion*	
10:40-11:00	Case-based lecture Asciminib third line - which patients will benefit?	Delphine Rea (Paris)
11:00-11:05	*Discussion*	
11:05-11:25	Case-based lecture Asciminib first line in combination - the FASCINATION trial	Thomas Ernst (Jena)
11:25-11:30	*Discussion*	
11:30-11:50	Case-based lecture New drugs and patient reported outcome	Valentin Garcia-Gutierrez (Madrid)
11:50-11:55	*Discussion*	
11:55-12:02	Interactive case Vodobatinib in CML	Franck Nicolini (Lyon)
12:02-12:05	*Discussion*	
12:05-12:10	Brief oral communication A retrospective comparison of patient outcomes on pacritinib versus ruxolitinib in patients with myelofibrosis and thrombocytopenia	Marta Sobas (Wroclaw)
12:10-12:13	*Discussion*	

12:13-12:35 Panel discussion

12:35-14:25 Lunch

13:15-14:15 **SATELLITE SYMPOSIUM**
Expert perspectives: Ongoing unmet needs and future advances in myelofibrosis treatment
Chair: John Mascarenhas (New York)
Speakers: Florian Heidel (Jena), Alessandro Vannucchi (Florence)

This symposium is organized and sponsored by Bristol Myers Squibb

14:25-15:20 ROUNDTABLE 2 – Indications for allogeneic stem cell transplantation
Chair: Andreas Hochhaus (Jena)

14:25-14:40	CML	Martin Bornhäuser (Dresden)
14:40-14:55	Primary myelofibrosis	Nicolaus Kröger (Hamburg)
14:55-15:10	Advanced MPN	Vikas Gupta (Toronto)
15:10-15:20	*Discussion*	

15:20-16:00 DEBATE 2 – Fixed combination of induction chemotherapy + TKI for blast phase CML
Chair: Thomas Ernst (Jena)

Audience votes

15:20-15:35	PRO	Mhairi Copland (Glasgow)
15:35-15:50	CON	Susanne Saussele (Mannheim)
15:50-16:00	*Discussion*	

Audience votes again

16:00-16:30 Coffee break

SESSION V- Immunology, Infections in CML and MPN
Chair: Massimo Breccia (Rome)

16:30-16:37	Interactive case Comorbidity in CML/MPN	Massimo Breccia (Rome)
16:37-16:40	*Discussion*	
16:40-17:00	Case-based lecture Second malignancies and TK inhibition	Francesca Palandri (Bologna)
17:00-17:05	*Discussion*	
17:05-17:25	Case-based lecture Ruxolitinib and hyperinflammation	Tiziano Barbui (Bergamo)
17:25-17:30	*Discussion*	
17:30-17:40	Brief study report RuxCoFlam: Ruxolitinib in COVID 19 induced hyperinflammation	Sebastian Birndt (Jena)
17:40-17:45	*Discussion*	
17:45-18:05	Case-based lecture Infections in MPN/CML patients	Carl Crodel (Jena)
18:05-18:10	*Discussion*	

18:10-18:15	Brief oral communication Values and preferences towards antithrombotic therapy in patients with myeloproliferative neoplasms: a qualitative study	Jonah Rakoff (Hamilton)
18:15-18:18	*Discussion*	
18:18-18:23	Brief oral communication Stem cell-derived gene expression scores predict survival and leukemic transformation in myelofibrosis	Jessie Medeiros (Toronto)
18:23-18:26	*Discussion*	
18:26-18:45	*Panel discussion*	

Sunday, March 5, 2023

07:50-08:50 Simultaneous Breakfast Meet the Expert Sessions

1. **Clonal Hematopoiesis and MPNs** — Jyoti Nangalia (Hinxton)
2. **MPN-MDS Overlap in 2023** — Michael Savona (Nashville)
3. **CML late line therapy** — Massimo Breccia (Rome)

09:00-10:00 **SATELLITE SYMPOSIUM**
Managing Myelofibrosis: Can We Do More to Address Cytopenias, Reduce Transfusion Burden, and Improve Quality of Life?
Chair: Mary Frances McMullin (Belfast)
Speakers: Jean Jacques Kiladjian (Paris), Alessandro Vannucchi (Florence)

This symposium is organized by PeerVoice and supported by an educational grant from GSK plc and CTI BioPharma Corp.

SESSION VI – Treatment free remission
Chair: Satu Mustjoki (Helsinki)

10:10-10:17	Interactive case Are all BCR::ABL1 alike?	Satu Mustjoki (Helsinki)
10:17-10:20	*Discussion*	
10:20-10:40	Case-based lecture How to increase eligibility for treatment free remission?	Giuseppe Saglio (Turin)
10:40-10:45	*Discussion*	
10:45-11:05	Case-based lecture How to target stem cell persistence in CML?	Tim Brümmendorf (Aachen)
11:05-11:10	*Discussion*	
11:10-11:30	Case-based lecture Is treatment free remission the goal in polycythemia vera?	Francesca Palandri (Bologna)
11:30-11:35	*Discussion*	
11:35-11:42	Interactive case Is treatment free remission feasible in eosinophilic leukemias?	Andreas Reiter (Mannheim)
11:42-11:45	*Discussion*	

11:45-11:50	Brief oral communication Outcomes of discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients: multicenter experience in Taiwan	Ning-Chun Chen (Taiwan)
11:50-11:53	*Discussion*	

11:53-12:15 Panel discussion

12:15-13:00 Keynote lecture
Chair: Andreas Hochhaus (Jena), Ruben Mesa (Winston Salem)

12:15-12:45	Virchows cellular pathology 2.0	Nikolaus Rajewsky (Berlin)
12:45-13:00	Discussion	

13:00-13:10 Closing remarks Conference Chairpersons

MEETING CLOSURE